Cigna/Express Scripts Gene Therapy Solution Involves Plans ‘Pre-Paying’ For Coverage

Approach designed to avoid price “shock” when coverage for Luxturna or Zolgensma is requested. Plans would agree to certain per member per month payments to enroll in the program, which would cover both plan and patient costs for gene therapy.

Lightning-strike
Program Will Ensure Coverage When Needed

The Cigna Corp. Health Services business will launch a solution in 2020 for covering high cost gene therapies in which payers enroll and make monthly per member payments into a newly dedicated program that would cover the cost of gene therapy in the future if they have a member who needs treatment.

The program will be administered primarily by Cigna’s eviCore specialty medical management business, which is part of Express Scripts...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By 

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

More from Advanced Therapies

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By 

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By 

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.